Status:
RECRUITING
Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke
Lead Sponsor:
General Hospital of Shenyang Military Region
Conditions:
Stroke, Ischemic
Eligibility:
All Genders
40+ years
Phase:
NA
Brief Summary
The goal of this clinical trial is to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.
Detailed Description
Stroke is the second leading cause of death and the third leading cause of death and disability combined in the world. The remote ischemic preconditioning (RIC) procedure is low-cost with excellent pr...
Eligibility Criteria
Inclusion
- 1\. Age over 40 years old;
- 2\. Diagnosed with ischemic stroke (including TIA and cerebral infarction), with onset time of more than 1 month;
- 3\. Culprit arteries are the large arteries of the anterior circulation with atherosclerotic stenosis (≥50%) or occlusion;
- 4\. ASITN/SIR collateral circulation of 0-3 based on DSA evaluation;
- 5\. First onset or prior onset with no significant sequelae (mRS ≤ 2);
- 6\. Those who are not expected to undergo angioplasty within 12 months (judged by the doctor or decided by patients and/or their representatives);
- 7\. The availability of informed consent.
Exclusion
- 1\) Patients with severe infection or serious diseases such as liver, kidney, hematopoietic system, endocrine system, etc.;
- 2\) Patients with a history of stroke and severe sequelae (mRS≥3);
- 3\) arterial stenosis due to aortic dissection, moyamoya disease; Any known vasculitic disease; herpes zoster, varicella-zoster or other viral infections with vascular lesions; neurosyphilis; other intracranial infections; any intracranial artery stenosis associated with hypercytosis of cerebrospinal fluid; radiation-induced vascular lesions; myofiber dysplasia; sickle cell disease; neurofibromas; benign vascular lesions of the central nervous system; postpartum vascular disease; stenosis of the intracranial arteries due to vasospasm or thrombosm;
- 4\) Uncontrolled severe hypertension (systolic pressure≥180mmHg or diastolic pressure≥110 mmHg after drug treatment) ;
- 5\) Subclavian artery stenosis ≥50% or subclavian artery steal syndrome;
- 6\) Patients with intracranial hemorrhage (parenchymal hemorrhage, subarachnoid hemorrhage, subdural/epidural hemorrhage) within 90 days before enrollment;
- 7\) Intracranial tumor, arteriovenous malformation, or aneurysm;
- 8\) Patients with severe hematologic diseases or severe coagulation abnormalities;
- 9\) Retinal hemorrhage or visceral hemorrhage within 30 days;
- 10\) Those who are expected to undergo major surgery (including femoral artery, cardiac, aortic or carotid artery surgery) within 30 days before enrollment or within 12 months after enrollment;
- 11\) Those who have received stent implantation, angioplasty or other related medical devices for the target diseased blood vessels, or those who are expected to undergo the above treatments within 12 months after enrollment;
- 12\) Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.
- 13\) Damage and lesions in the cerebral veins;
- 14\) Pregnant or lactating women;
- 15\) Those who are participating in other clinical trials within 3 months;
- 16\) Life expectancy is less than 1 year
- 17\) Patients not suitable for this clinical studies considered by researcher
Key Trial Info
Start Date :
June 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06170944
Start Date
June 1 2024
End Date
January 30 2026
Last Update
August 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Hospital of Northern Theater Command
Shenyang, China, 110840